Search Results

• • 15 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Integrated health systems and evidence-based care: standardizing treatment to eliminate cancer disparities

  Authors:Manali I Patel and Kim F RhoadsFrom:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20152,152 words Report 1650LAuthor(s): Manali I Patel aff1 , Kim F Rhoads [*] aff2 KEYWORDS cancer; disparities; evidence-based care; health equity Historical explanations for disparities: are we running in place or falling behind?...

• Secretory breast carcinoma in a 41-year-old man with long-term follow-up: a special report

  Authors:Guanqiao Li, Xiaojie Zhong, Jia Yao, Jimin Chen, Mei Wang, Haiying Liu, et al.From:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20154,598 words Clinical report 1520LAuthor(s): Guanqiao Li aff1 , Xiaojie Zhong aff1 , Jia Yao aff1 , Jimin Chen aff2 , Mei Wang aff1 , Haiying Liu aff1 , Shiping Yang [*] aff3 KEYWORDS breast; clinical feature; male; secretory carcinoma; treatment...

• Prognostic factors in patients with recurrent or metastatic retroperitoneal leiomyosarcoma

  Authors:Qian Li, Rongyuan Zhuang, Jun Zhu, Weiqi Lu, Yingyong Hou, Ju Liu, et al.From:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20154,731 words Report 1550LAuthor(s): Qian Li aff1 , Rongyuan Zhuang aff1 , Jun Zhu aff2 , Weiqi Lu aff2 , Yingyong Hou aff3 , Ju Liu aff3 , Yong Zhang aff2 , Yan Wang aff1 , Tianshu Liu aff1 , Zhiming Wang aff1 , Yuhong Zhou [*] aff1 KEYWORDS...

• Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?

  Authors:Loredana Lorusso and Kate NewboldFrom:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20155,654 words Report 1670LAuthor(s): Loredana Lorusso aff1 , Kate Newbold [*] aff1 KEYWORDS E7080; lenvatinib; thyroid cancer; tyrosine kinase inhibitor treatment Thyroid cancer is the most common endocrine neoplasia and it represents...

• Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer

  Authors:Guy Jerusalem, Andree Rorive, and Joelle CollignonFrom:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20158,362 words Report 1450LAuthor(s): Guy Jerusalem [*] aff1 , Andrée Rorive aff2 , Joëlle Collignon aff2 KEYWORDS capecitabine; chemotherapy; eribulin; etirinotecan pegol; gemcitabine; irinotecan; ixabepilone; metastatic breast cancer;...

• Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives

  Authors:Silvia Ortolani, Chiara Ciccarese, Sara Cingarlini, Giampaolo Tortora, and Francesco MassariFrom:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 201514,603 words Report 1890LAuthor(s): Silvia Ortolani aff1 , Chiara Ciccarese aff1 , Sara Cingarlini aff1 , Giampaolo Tortora aff1 , Francesco Massari [*] aff1 KEYWORDS everolimus; mTOR inhibitors; mTOR pathway; neuroendocrine neoplasm;...

• Corrigendum

  From:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 2015141 words Brief article, Corre... 1820LFollowing publication of the Research Article by Orazio Caffo, Giovanni Lo Re, Teodoro Sava, Sebastiano Buti, Cosimo Sacco, Umberto Basso, Fable Zustovich, Michele Lodde, Alessandra Perin, Gaetano Facchini, Antonello...

• Schwannomas exhibit distinct size-dependent gene-expression patterns

  Authors:Ruty Mehrian-Shai, Shany Freedman, Soheil Shams, Joni Doherty, William Slattery, Nancy Ya-Hsuan Hsu, et al.From:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20154,980 words Report 1710LAuthor(s): Ruty Mehrian-Shai [*] aff1 , Shany Freedman aff1 , Soheil Shams aff2 , Joni Doherty aff3 , William Slattery aff4 , Nancy Ya-Hsuan Hsu aff5 , Juergen KV Reichardt aff6 , Ali Andalibi aff7 , Amos Toren aff1...

• Living outliers: experiences, insights and narratives of exceptional survivors of incurable cancer

  Authors:Moshe Frenkel, Sky Gross, Ariela Popper Giveon, Kenneth Sapire, and Doron HermoniFrom:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20156,672 words Report 1390LAuthor(s): Moshe Frenkel [*] aff1 aff2 , Sky Gross aff3 , Ariela Popper Giveon aff4 , Kenneth Sapire aff5 , Doron Hermoni aff6 KEYWORDS alternative medicine; cancer care; cancer survival; complementary medicine;...

• An update on miRNAs as biological and clinical determinants in colorectal cancer: a bench-to-bedside approach

  Authors:Wenhao Weng, Junlan Feng, Huanlong Qin, Yanlei Ma, and Ajay GoelFrom:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 201513,237 words Report 1830LAuthor(s): Wenhao Weng aff1 , Junlan Feng aff2 , Huanlong Qin aff3 , Yanlei Ma aff3 , Ajay Goel [*] aff4 KEYWORDS carcinogenesis; clinical application; colorectal cancer; diagnosis; miRNA; predictive biomarkers;...

• Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia

  Authors:Naresh Bumma, Nikolaos Papadantonakis, and Anjali S AdvaniFrom:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20157,551 words Report 1720LAuthor(s): Naresh Bumma aff1 , Nikolaos Papadantonakis aff2 , Anjali S Advani [*] aff2 KEYWORDS acute lymphoblastic leukemia; bispecific antibody; blinatumomab; minimal residual disease; relapse The incidence...

• Clonal diversity in glioblastoma: is it clinically relevant?

  Author:Colin WattsFrom:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20152,228 words Report 2070LAuthor(s): Colin Watts [*] KEYWORDS brain; cancer; cancer stem cells; clinical trials; evolution; genomics; glioblastoma; sampling bias; therapy Glioblastoma (GBM), the most common primary brain cancer, is...

• Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review

  Authors:Omar Abdel-Rahman and Mona FouadFrom:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20158,574 words Report 1510LAuthor(s): Omar Abdel-Rahman [*] aff1 , Mona Fouad aff2 KEYWORDS GIST; imatinib; salvage treatment; second line; systemic treatment; third line Gastrointestinal stromal tumor (GIST) is the most common...

• PARK2 gene and familial lung cancer: what is the link?

  Authors:Donghai Xiong, Yian Wang, and Ming YouFrom:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20152,413 words Report 2420LAuthor(s): Donghai Xiong aff1 aff2 , Yian Wang aff1 , Ming You [*] aff1 aff2 KEYWORDS exome sequencing; familial lung cancer; genomics; mutations; PARK2 PARK2 has tumor suppressive role in cancer In general,...

• Advanced prostate cancer: Every Voice Matters

  From:Future Oncology (Vol. 11, Issue 12) Peer-Reviewed

  June 20151,771 words Interview 1470LAuthor(s): Heather Payne [*] KEYWORDS advanced prostate cancer; Astellas; Every Moment Matters; Every Voice Matters; prostate cancer; quality of life Q Can you tell our readers about your career to date & what...